CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Regina Jitschin 1, Domenica Saul 1, Martina Braun 1, Sehmus Tohumeken 1, Simon Völkl 1, Roman Kischel 2, Michael Lutteropp 2, Cedric Dos Santos 3, Andreas Mackensen 1 and Dimitrios Mougiakakos 1*

Abstract
Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacting disease outcome. Over the last years myeloid derived suppressor cells (MDSCs) have been gaining momentum in the field of cancer research. MDSCs are a heterogeneous cell population morphologically resembling either monocytes or granulocytes and sharing some key features including myeloid origin, aberrant (immature) phenotype, and immunosuppressive activity. Increasing evidence suggests that accumulating MDSCs are involved in hampering anti-tumor immune responses and immune-based therapies. Here, we demonstrate increased frequencies of CD14+ monocytic MDSCs in newly diagnosed AML that co-express CD33 but lack HLA-DR (HLA-DRlo). AML-blasts induce HLA-DRlo cells from healthy donor-derived monocytes in vitro that suppress T-cells and express indoleamine-2,3-dioxygenase (IDO). We investigated whether a CD33/CD3-bispecific BiTE® antibody construct (AMG 330) with pre-clinical activity against AML-blasts by redirection of T-cells can eradicate CD33+ MDSCs. In fact, T-cells eliminate IDO+CD33+ MDSCs in the presence of AMG 330. Depletion of total CD14+ cells (including MDSCs) in peripheral blood mononuclear cells from AML patients did not enhance AMG 330-triggered T-cell activation and expansion, but boosted AML-blast lysis. This finding was corroborated in experiments showing that adding MDSCs into co-cultures of T- and AML-cells reduced AML-blast killing, while IDO inhibition promotes AMG 330-mediated clearance of AML-blasts. Taken together, our results suggest that AMG 330 may achieve anti-leukemic efficacy not only through T-cell-mediated cytotoxicity against AML-blasts but also against CD33+ MDSCs, suggesting that it is worth exploring the predictive role of MDSCs for responsiveness towards an AMG 330-based therapy.

Keywords: Acute myeloid leukemia, Myeloid derived suppressor cells, Bispecific antibodies

Main text
Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults. The disease course is typically aggressive and despite therapeutic advances only 30% of the patients will be long-term survivors. Emerging evidence suggests that immune evasion in AML favors relapse and could antagonize novel immunotherapeutic concepts [1].

Over the last years, myeloid derived suppressor cells (MDSCs) have been gaining momentum in cancer research as promoters of tumor immune escape. MDSCs represent a heterogeneous population that morphologically resembles monocytes or granulocytes sharing some features: myeloid origin, immature phenotype, and T-cell suppressive activity. Accumulating MDSCs have been described in AML patients [2], in myelodysplasia (MDS) [3], and in murine AML models [4]. In fact, AML-blasts hold the potential to induce MDSCs (from conventional monocytes) by exosomal transfer of MUC-1 [2]. These cells could contribute to immune escape partly explaining why AML-blasts despite expressing antigens recognizable to host T-cells (e.g. WT1) rarely are eradicated by the host’s immune system [5]. Targeting MDSCs in preclinical
cancer models has shown efficacy in delaying disease thus suggesting further clinical exploitation [6].

Bispecific T-cell engaging (BiTE®) antibody constructs simultaneously target tumor antigens of interest and the T-cell receptor complex. T-cells can be recruited in an antigen-independent manner [7]. The first BiTE® developed against CD33, which is expressed on the majority of AML-blasts, is AMG 330 (Amgen, Thousand Oaks, CA). Preclinical studies revealed its capacity to recruit and to expand autologous T-cells leading to AML-blasts lysis [8, 9]. In fact, CD33 might have an advantage over other targets (e.g. CD123) since it is also expressed on monocytic MDSCs [10]. In this study we sought out to investigate whether AMG 330 could simultaneously confer two hits by redirecting T-cells against both CD33+ AML-blasts and CD33+ MDSCs thereby further enhancing anti-leukemic immune activity.

First, CD14+CD11b+CD33+ monocytic cells expressing low levels of HLA-DR (HLA-DRlo) and resembling one of the most established human MDSC-like phenotype [11] as previously described by us in chronic lymphocytic leukemia (CLL) and malignant melanoma [10, 12] were quantified in the peripheral blood of patients with newly diagnosed AML. A representative flow cytometry (FACS)-based gating strategy is displayed in Fig. 1a, whereby AML-blasts were defined as CD117+ and/or CD34+ cells during initial AML diagnosis. The proportion of HLA-DRlo cells among monocytes was significantly increased in AML patients as compared to healthy controls (HD) (28.98 ± 4.19%, n = 13 versus 3.28 ± 0.75%, n = 37) in line with previous observations [2]. In fact, MDSCs can be cytogenetically related to the malignant AML clone as recently reported [2]. Percentage of aberrant monocytes did not correlate (positively) with the frequency of circulating myeloid blasts or (negatively) with the frequency of T-cells in contrast to findings from CLL [10], B-NHL [13], and MDS [3] (Fig. 1b).

CD14+ monocytes isolated from HD were co-cultured for three to five days with AML cell-lines (OCI-AML3, HL-60, and MOLM-13/cAML) or primary AML-blasts (pAML) that were previously labeled with a vital dye for better discriminating both populations in ultra-low attachment surface plates allowing full recovery of monocytes. Presence of AML-blasts led (at day five) to a significant reduction of HLA-DR expression in CD14+ monocytes (Fig. 1c). Previous studies as for example in CLL and in patients following allogeneic stem cell transplantation have shown that the monocytic MDSCs can express indoleamine-2,3-dioxygenase (IDO) [10, 14]. In fact, IDO-mediated tryptophan depletion and production of kynurenine can modulate T-cell responses. Furthermore, IDO has been shown to negatively impact efficacy of immune-based therapies such as of T-cells carrying chimeric antigen receptors [15] while high kynurenine concentrations predict an unfavorable outcome in AML patients [16]. We detected a significant IDO upregulation on the gene expression and protein level in monocytes upon contact to cAML- and pAML-blasts (Fig. 1d). As anticipated, the functional assessment of AML-educated monocytes co-cultured at different ratios with activated autologous T-cells revealed a strong T-cell suppressive activity (as compared to non-AML-educated monocytes), which is in line with their MDSC-like phenotype (Fig. 1e) and with previous observations in AML [2], allowing us to denominate them as induced MDSCs (iMDSCs).

Next, we separated the HLA-DRhi and HLA-DRlo fraction among the bulk of AML-educated monocytes using FACS-based cell sorting and then repeated the T-cell suppression assays. Here, we observed that the HLA-DRlo subset still holds the strongest T-cell suppressive capacity further confirming the enhanced regulatory features of HLA-DRlo monocytic iMDSCs (Fig. 1f).

We further assessed whether T-cells can be engaged by AMG 330 to target autologous monocytes and/or T-cell suppressive (AML-educated) iMDSCs. Noticeably, previous studies have shown that AMG 330-mediated lysis is co-determined by the cell surface CD33 levels [8, 9]. The median fluorescence intensity (MFI) of CD33 as assessed by flow cytometry was comparable in both the HLA-DRlo (MDSCs) and HLA-DRhi CD14+ subsets (Fig. 1g). Purified CD3+ T-cells engaged by AMG 330 were able to form immunological synapses with autologous CD14+ cells as revealed by the F-actin and perforin polarization (Fig. 1h) and which is an important determinant for the efficacy T-cell based immune therapies [17]. Specific lysis of calcein-labeled HD-derived monocytes triggered by AMG 330 in presence of autologous T-cells was at comparable levels as for their iMDSC counterparts that had been previously educated by AML cell-lines and despite their elevated IDO expression and their T-cell suppressive activity (Fig. 1d-e, i).

In order to validate the AMG 330-triggered redirection of T-cells towards CD33+ AML-blasts AMG-PBMC samples from newly diagnosed patients were used for short-term (three to six days) cell cultures in presence of control BiTE® constructs or AMG 330. In line with previous reports [8, 9], AMG 330 treatment resulted in an efficient elimination of CD33+ AML-blasts and the concomitant expansion of residual autologous T-cells (Fig. 2a). Most parameters that are indicative for T-cell activation (e.g. CD25 and CD69), cytotoxic activity (e.g. granzyme B and CD107), or cytokine production (e.g. IL2 and IFNγ) as well as the bystander activation of NK-cells (by
Fig. 1 (See legend on next page.)
amongst others abundant pro-inflammatory cytokines) were found upregulated upon AMG 330 application when phenotypically analyzing T- and NK-cells within the AML-PBMCs by FACS (Fig. 2b). The initial T-cell frequency within the PBMCs ranging from 0.16 to 14.30% and/or the initial MDSC levels had both no impact on the assessed levels of T-cell responsiveness (Additional file 1: Tables S1 and S2).

We next hypothesized that CD33⁺IDO⁺ MDSCs might antagonize AMG 330 efficacy by (A) competing over the target antigen CD33 or by (B) suppressing successfully recruited T-cells (by IDO). Using a FACS-based indirect QIFIKIT⁺ immuno-fluorescence assay we quantified the CD33 cell surface antigen density (which is comparable for monocytes and AML-MDSCs, Fig. 1g) on primary AML-blasts and on CD14⁺ cells and indeed observed higher (potentially competing) CD33 levels on CD14⁺ cells (Fig. 2c). Concomitant blocking of the IDO activity using epacadostat in AML patient-derived PBMCs treated with AMG 330 resulted in a significantly enhanced reduction of the CD33⁺ cell count (Fig. 2d). Depleting all CD14⁺ cells (including monocytes MDSCs) in AML-PBMCs prior to AMG 330 treatment did not have a detectable effect on T-cell activation or their production of cytokines as well as T-cell expansion (Fig. 2e), which has been shown to be highly relevant for the clinical activity of BiTE⁺ antibody constructs [18]. However, removal of all CD14⁺ cells led to an increased AMG 330-mediated lysis (Fig. 2f). For further investigating this phenomenon (in terms of being total CD14⁺ cell- or rather MDSC-driven), we cultured MOLM13 cells (cAML) with HD-derived T-cells and added AMG 330 in the presence of autologous HD-derived CD33⁺ monocytes or CD33⁺ iMDSCs. Co-cultures were performed for three days for preventing a reprogramming of the conventional monocytes into MDSCs that was occurring at day five (Fig. 1c and d). We observed a reduced specific lysis of MOLM13 cells only in co-cultures with iMDSCs (Fig. 2g) suggesting (at least ex vivo) a specifically MDSC-mediated (presumably only transient until MDSCs are eliminated by the redirected T-cells) reduction of AMG 330 efficacy most likely due to the MDSCs’ direct T-cell suppressive activity and not due to competition over the target antigen CD33 (which is found on both conventional monocytes and iMDSCs). At the same time BiTE-triggered lysis of iMDSCs and monocytes as shown in Fig. 1i remained unaffected in presence of MOLM13 AML-cells (Fig. 2h).

Taken together, our preclinical data suggests that AMG 330 could achieve anti-leukemic activity not only through direct engagement of T-cells but also via targeting of CD33⁺ monocyctic MDSCs [1]. In accordance with our findings, recent preliminary data indicate that elimination of MDSCs by the bispecific CD33/CD3 T-cell engager AMV564 also restores immune homeostasis in MDS [19]. Furthermore, it remains to be elucidated whether MDSCs impact in vivo (at least temporarily until their AMG 330-triggered elimination) AMG 330 efficacy. In the latter case, MDSC levels could represent a biomarker for the patients’ clinical responsiveness towards an AMG 330-based therapy in analogy to observations from other immunotherapies such as peptide vaccination in renal cancer [20].
Fig. 2 AMG 330 triggers T-cell-mediated lysis of AML-blasts that is further enhanced by MDSC depletion. (a) The absolute number of CD33+ AML-blasts and CD3+ T-cells was quantified in patient-derived AML PBMCs (n=10) after 6 days of treatment with control BiTE® antibodies (c) or AMG 330. (b) AML-derived PBMCs (n=12) after 6 days of treatment with control BiTE® antibodies or AMG 330. The median fluorescence intensity (MFI) of TNFα, granzyme B (grz B), CD107, perforin, CD69, CD137, IL2, and IFNγ was assessed by FACS in CD4+/CD8+ T-cells and CD56+/CD3neg NK-cells as indicated. The cells’ MFI from samples treated with control antibodies was set as 1. (c) CD33 surface antigen quantification was performed for AML-blasts and CD14+ monocytes (n=8). (d) AML-derived PBMCs (n=5) were treated with 10 pM AMG 330 in the presence or absence of the IDO inhibitor epacadostat (1 μM) and the number of CD33+ AML-blasts quantified. The graph displays the individual fold changes in cell numbers in presence of epacadostat. (e) AML PBMCs (n=7) with/without prior depletion of CD14+ cells were treated with AMG 330 for three days. Expansion index and MFI of CD69, CD137, CD25, CD154, IL2, and IFNγ were assessed by FACS in VPD450-labeled CD4+/CD8+ T-cells. Samples without depletion of CD14+ cells were set as 1. (f) AML-derived PBMCs (n=5) with/without prior depletion of CD14+ cells were treated with AMG 330 for six days. LDH release as a surrogate for cell lysis was measured in the cultures’ supernatants. (g) Calcein-labeled MOLM-13 cells (MOLM) were co-cultured with T-cells alone (upper illustration) or with T-cells together with autologous monocytes or AML-educated IMDCs (n=5) +/- AMG 330 (lower illustration). Specific lysis of MOLM-13 cells was assessed after 3 h. (h) Calcein-labeled monocytes or iMDSCs (n=4) were co-cultured with autologous T-cells and MOLM-13 cells +/- AMG 330. Specific lysis of monocytes/iMDSCs was assessed after 3 h. Bars indicate the standard error of the mean. Abbreviations: *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Additional file

**Additional file 1:** Table S1. Fluorochrome-coupled antibodies and/or chemical dyes for flow cytometry. Table S2. AML-derived PBMCs (n=12) were treated with AMG 330 for three days. The median fluorescence intensity (MFI) of granulocyte B (GrB B), CD107, perforin, CD69, CD137, CD25, CD154, IL2, IFNγ, and the cells’ expansion index was assessed by FACs in CD4+/CD8+ CD3+ T-cells as indicated. The association between those variables and the PBMCs’ initial frequency of CD3+ T-cells was calculated using a Pearson correlation analysis. Abbreviations: p, p-value; r, Pearson correlation. Table S3. AML-derived PBMCs (n=12) were treated with AMG 330 for three days. The median fluorescence intensity (MFI) of granulocyte B (GrB B), CD107, perforin, CD69, CD137, CD25, CD154, IL2, and IFNγ was assessed by FACs in CD4+/CD8+ CD3+ T-cells. The association between those variables and the PBMCs’ initial frequency of CD3+ T-cells was calculated using a Pearson correlation analysis. Abbreviations: p, p-value; r, Pearson correlation. (DOCK 50 kb)

**Abbreviations**

AML: Acute myeloid leukemia; CD: Cluster of differentiation; CLL: Chronic lymphocytic leukemia; FACS: Flow cytometry; IDO: Indoleamine-2,3-dioxygenase; MDS: Myelodysplastic syndrome; MDSC: Myeloid derived suppressor cell; PBMCs: Peripheral blood mononuclear cells

**Acknowledgements**

We acknowledge the kind assistance of the Core Unit Cell Sorting and Immunomonitoring Erlangen.

**Funding**

R.J. was supported by the I2KF Erlangen (Projekt j67). S.T. was supported by the "Titatger" graduate school of the Elitenetzwerk Bayern. D.M. was supported by the Else Kröner-Fresenius Foundation.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

RJ performed research, analyzed data, and helped writing the manuscript. DS, ST, and MB performed research and analyzed data. SV provided material. RK, ML, CDS, and AM helped designing the study, analyzed data, and helped writing the manuscript. DM designed the study, analyzed data, and wrote the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

All samples were collected upon approval by the local ethics committee (number: 3779/138_17B) and patients’ informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

RK and ML are employed by Amgen Research (Munich) GmbH. CDS is employed by Amgen Inc. RJ, AM, and DM were supported by research funding from Amgen Inc. The remaining authors declare no conflict of interest.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany. 2Amgen Research GmbH, Munich, Germany. 3Clinical Biomarkers and Diagnostics, Amgen Inc., South San Francisco, CA, USA.

**Received:** 3 August 2018 **Accepted:** 18 October 2018

**Published online:** 05 November 2018

**References**

1. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia. 2014;28(9):1784–92.
2. Pyzer AR, Stoopinsky D, Rajabi H, Washington A, Tagde A, Coll M, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129(13):1791–801.
3. Gleason MK, Ross JA, Warlick ED, Lund TC, Veneris MR, Wiemek A, et al. CD16/CD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123(19):3016–26.
4. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013;123(5):1999–2010.
5. Gaiger A, Reese V, Dils ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2003;101(6):1480–9.
6. Dominguez GA, Condamine T, Mony S, Hishimoto A, Wang F, Liu Q, et al. Selective targeting of myeloid-derived suppressor cells in Cancer patients using DS-827a, an agonistic TRAIL-R2 antibody. Clin Cancer Res. 2017;23(12):2942–50.
7. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941–4.
8. Laslo GS, Gudgeon CJ, Harrington KH, Dell’Aria J, Newhall KJ, Mears GO, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody. AMG 330, against human AML. Blood. 2014;123(4):554–61.
9. Krupka C, Kifer P, Kischel R, Zugmaier G, Lichteneregger FS, Kohnke T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30(2):484–91.
10. Jitschin R, Braun M, Buttmann T, Dettmerr-Wilde K, Bricks J, Berger J, et al. CLL-cells induce iODOhi CD144+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRreg. Blood. 2014;124(5):750–60.
11. Bronte V, Brandau S, Chen SH, Colombro MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
12. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiesling R, Immature immunosuppressive CD14+HLA-DR−/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70(11):4335–45.
13. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dextz AB. Immunosuppressive CD14+HLA-DRlow−/− monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(5):872–81.
14. Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, et al. Immunosuppressive CD14+HLA-DRlow/neq IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013;27(2):377–88.
15. Ninomiya S, Narita N, Huyu L, Yagou S, Savoldo B, Dotti G, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015;125(25):3905–16.
16. Mabuchi R, Hara T, Matsumoto T, Shibata Y, Nakamura N, Nakamura H, et al. High serum concentration of L-kyurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leukemia Lymphoma. 2016;57(1):192–8.
17. Xiong W, Chen Y, Kang X, Chen Z, Zheng P, Hsu YH, et al. Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther. 2018;26(4):963–75.
18. Zugmaier G, Gorkuget N, Klinger M, Viadrat A, Stelljes M, Neumann S, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–84.
19. Cheng P, Besaglo E, Chen X, Wei M, Guenot J, Fox J, et al. Immunodepletion of MDSC by AMG564, a novel tetavalent bispecific CD33/CD3 T-cell engager restores immune homeostasis in MDS in vitro. Blood. 2017;130(Suppl 1):51.
20. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multiparamete immune response to cancer vaccine iMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254–61.